Joep J de Jong1, Joost L Boormans1, Bas W G van Rhijn2, Roland Seiler3, Stephen A Boorjian4, Badrinath Konety5, Trinity J Bivalacqua6, Thomas Wheeler7, Robert S Svatek8, James Douglas9, Jonathan Wright10, Marc Dall'Era11, Simon J Crabb12, Jason A Efstathiou13, Michiel S van der Heijden14, Kent W Mouw15, David T Miyamoto16, Yair Lotan17, Peter C Black18, Ewan A Gibb19, Sima P Porten20. 1. Department of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. 2. Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 3. Department of Urology, University Hospital Bern, Bern, Switzerland. 4. Department of Urology, Mayo Clinic, Rochester, MN, USA. 5. Department of Urology, University of Minnesota, MD, USA. 6. Department of Urology, Johns Hopkins, Baltimore, MD, USA. 7. Department of Pathology, Baylor College of Medicine, Houston, TX, USA. 8. Department of Urology, UT San Antonio, San Antonio, TX, USA. 9. Department of Urology, University Hospital of Southampton, Hampshire, UK. 10. Department of Urology, University of Washington, Seattle, WA, USA. 11. Department of Urology, University of California Davis, Davis, CA, USA. 12. Cancer Sciences Unit, University of Southampton, Southampton, UK. 13. Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA. 14. Netherlands Cancer Institute, Amsterdam, The Netherlands. 15. Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA. 16. Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 17. Department of Urology, UT Southwestern Medical Center, Dallas, TX, USA. 18. Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. 19. Decipher Biosciences, Vancouver, BC, Canada. 20. Department of Urology, University of California San Francisco, San Francisco, CA, USA. Electronic address: Sima.Porten@ucsf.edu.
Abstract
Muscle-invasive bladder cancer (MIBC) is a sex-biased cancer with a higher incidence in men but worse outcomes in women. The root cause behind these observations remains unclear. To investigate whether sex-specific tumor biology could explain the differences in clinical behavior of MIBC, we analyzed the transcriptome profiles from transurethral resected bladder tumors of 1000 patients. Female tumors expressed higher levels of basal- and immune-associated genes, while male tumors expressed higher levels of luminal markers. Using molecular subtyping, we found that the rates of the basal/squamous subtype were higher in females than in males. Males were enriched with tumors of the luminal papillary (LumP) and neuroendocrine-like subtypes. Male MIBC tumors had higher androgen response activity across all luminal subtypes and male patients with LumP tumors were younger. Taken together, these data confirm differences in molecular subtypes based on sex. The role of the androgen response pathway in explaining subtype differences between men and women should be studied further. PATIENT SUMMARY: We explored the sex-specific biology of bladder cancer in 1000 patients and found that women had more aggressive cancer with higher immune activity. Men tended toward less aggressive tumors that showed male hormone signaling, suggesting that male hormones may influence the type of bladder cancer that a patient develops.
Muscle-invasive bladder cancer (MIBC) is a sex-biased cancer with a higher incidence in men but worse outcomes in women. The root cause behind these observations remains unclear. To investigate whether sex-specific tumor biology could explain the differences in clinical behavior of MIBC, we analyzed the transcriptome profiles from transurethral resected bladder tumors of 1000 patients. Female tumors expressed higher levels of basal- and immune-associated genes, while male tumors expressed higher levels of luminal markers. Using molecular subtyping, we found that the rates of the basal/squamous subtype were higher in females than in males. Males were enriched with tumors of the luminal papillary (LumP) and neuroendocrine-like subtypes. Male MIBC tumors had higher androgen response activity across all luminal subtypes and male patients with LumP tumors were younger. Taken together, these data confirm differences in molecular subtypes based on sex. The role of the androgen response pathway in explaining subtype differences between men and women should be studied further. PATIENT SUMMARY: We explored the sex-specific biology of bladder cancer in 1000 patients and found that women had more aggressive cancer with higher immune activity. Men tended toward less aggressive tumors that showed male hormone signaling, suggesting that male hormones may influence the type of bladder cancer that a patient develops.
Authors: Leslie K Ballas; Stephanie Navarro; Chunqiao Luo; Croix C Fossum; Albert Farias; Siamak Daneshmand; Susan Groshen Journal: Cancer Med Date: 2021-03-28 Impact factor: 4.452
Authors: Léa Deltourbe; Livia Lacerda Mariano; Teri N Hreha; David A Hunstad; Molly A Ingersoll Journal: Mucosal Immunol Date: 2022-07-22 Impact factor: 8.701
Authors: Joseph L Sottnik; Lauren Vanderlinden; Molishree Joshi; Ana Chauca-Diaz; Charles Owens; Donna E Hansel; Colin Sempeck; Debashis Ghosh; Dan Theodorescu Journal: Cancer Res Date: 2021-03-09 Impact factor: 13.312
Authors: Alejandra Bernardini; Marta Dueñas; María Cruz Martín-Soberon; Carolina Rubio; Cristian Suarez-Cabrera; Raquel Ruiz-Palomares; Ester Munera-Maravilla; Sara Lázaro; Iris Lodewijk; Daniel Rueda; David Gómez-Sánchez; Teresa Alonso-Gordoa; Javier Puente; Álvaro Pinto; Pilar González-Peramato; Carlos Aguado; Mercedes Herrera; Flora López; Victor M G Martinez; Lucía Morales; Daniel Castellano; Jesús M Paramio; Guillermo de Velasco Journal: Cancers (Basel) Date: 2022-01-13 Impact factor: 6.639
Authors: Carina Bernardo; Fátima L Monteiro; Inês Direito; Francisco Amado; Vera Afreixo; Lúcio L Santos; Luisa A Helguero Journal: Front Endocrinol (Lausanne) Date: 2021-10-08 Impact factor: 5.555